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Abstract 
Background: Since the first attempts of kidney transplant, the inflammation mediated by T lymphocytes was considered 
one of the most important processes implicated in graft rejection but, multiple acute and chronic graft rejects revealed that the 
inflammation process is not singular and humoral mechanisms may play a role in the development of chronic vascular rejection.  
Material and methods: We evaluated 500 Romanian patients registered on the kidney transplant waiting list. We 
performed anti-HLA class I and class II antibodies screening and identification. Laboratory tests were performed at Centre for 
Immunogenetics and Virology, Fundeni Clinical Institute, Bucharest, Romania. The methods used are represented by ELISA (GTI 
Diagnosis, USA) and Luminex (Tepnel, USA) 
Results: pretransplant evaluation of the subjects illustrates that 145 patients (29%) have been sensitized and 355 patients 
(71%) have not been sensitized. The most frequent types of anti-HLA antibodies were A2 (13%), B42 (10%), DR7 and DR11 (13%). 
Post transplant, the most cases with de novo antibodies were observed in the first 6 months post transplantation. High serum levels 
of Il-2Receptor, TNF-α and neopterin in post transplant sensitized patients were observed following de novo cytotoxic antibodies 
occurrence. 
Conclusion: post renal transplantation, patients present high risk in developing de novo cytotoxic antibodies, especially 
those who had HLA mismatch with the donor. These antibodies are predictors for acute graft rejection and for graft failure. 
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Introduction 
Generalities 
 
The first successful kidney transplantation has 
been performed in Boston in 1954 between genetically 
identical twins. In Romania, the first renal transplant was 
carried out by Professor Dr. Eugen Proca in 1980 at 
Fundeni Clinical Institute. In 1997 has been made the first 
cadaveric renal transplant following multiple organs 
harvesting. In 1998, the first renal transplant in a diabetic 
patient was achieved. In the same year the first kidney 
transplant in an adult with chronic renal insufficiency due 
to cancer was performed. The performances continued 
and in 1999, the first kidney transplant in a child from a 
deceased person took place. In 2005 the first renal 
transplant in an anephric child due to bilateral Wilms 
tumor was performed. 
Since the first attempts of kidney transplant, the 
inflammation mediated by T lymphocytes was considered 
one of the most important processes implicated in graft 
rejection. Therefore, anti rejection therapies were directed 
against T lymphocytes. By using these therapies has 
decreased the rate of acute rejection and has significantly 
increased post transplant survival at one year. 
Nevertheless, the multiple acute and chronic graft rejects 
revealed that the inflammation process is not singular. 
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complement reveal, at the graft, antibodies depositions 
and consecutive complement activation [1]. 
HLA-A, HLA-B, HLA-DR compatibility does not 
guarantee kidney transplant free of rejection. At this 
moment, anti-HLA antibodies detection and identification 
represents one of the most important points in transplant 
research.  
 
The HLA system 
The human leukocyte antigen system (HLA) is 
the name of the major histocompatibility complex (MHC) 
in humans. The superlocus contains a large number of 
genes related to immune system function in humans. This 
group of genes resides on chromosome 6 and encodes 
cell-surface antigen-presenting proteins and many other 
proteins. MHC molecules are divided into 2 main classes: 
HLA class I antigens (HLA-A, HLA-B, HLA-C) - presented 
on the surface of all nucleated cells and platelets and HLA 
class II antigens (HLA-DR, HLA-DQ, HLA-DP, HLA-DM, 
HLA-DO) –  expressed on professional antigen-presenting 
cells, but also on the surface of endothelial vascular cells 
and renal tubular epithelial cells [2]. Due to the high 
polymorphism degree of the HLA system (more than 1600 
alleles), the individuals do not present identical sets of 
HLA molecules. HLA polymorphism confers 
immunological identity to each person and thus, the 
immune system can differentiates between “self” and “non 
self”. The involvement of HLA system in acceptance or 
rejection of the transplanted organ, represents a collateral 
consequence of its main function (in terms of 
immunological, a transplanted organ represents an 
immense pathological extracellular product)[3]. 
Before the era of new immunosuppressive 
drugs, transplantation in patients who had HLA 
configuration as close to the donor is accompanied by a 
better graft survival than less compatible recipient-donor 
pairs. However, the allocation of kidneys based on HLA 
match (especially for unrelated donors) may constitute a 
disadvantage for patients with a rare, unusual HLA 
phenotype. Due to high degree of HLA polymorphism 
rising chances of immunization because HLA molecules 
recognized as “no self” represent targets for the immune 
system. Cytotoxic antibodies (anti-HLA) do not occur 
naturally but after the blood/plasma transfusion, in 
pregnancy or after a previous transplant. Usually, the 
transfused women and with multiple pregnancies have 
high degree of sensitization by developing antibodies 
against multiple HLA antigens types [9]. When these 
antibodies are directed against HLA system of 
transplanted organ, their targets are represented by the 
graft endothelial cells. Next step is activation of 
complement, coagulation cascade and other inflammation 
factors, having as the final result severe injury of 
endothelial cells and dysfunction of the transplanted 
organ. This mechanism mediated by anti-HLA antibodies 
is called humoral rejection (hyperacute rejection). Thus, 
detection and ability to correctly identify these antibodies 
in sera of patients highly sensitized before transplantation 
is an important stage in determining immunological risk 
for recipient and for incompatible donor exclusion [4]. In 
the past, cytotoxic antibodies identification has been 
impaired by: (1) inability to distinguish between IgM and 
IgG antibodies; (2) correct identification of anti-HLA class 
II antibodies, especially in the presence of anti-HLA class 
I antibodies; (3) inability to detect the antibodies hidden by 
linkage disequilibrium. For example, in case of 
lymphocytotoxic tests, if all cells from a panel have HLA-
B8 and HLA-A1 phenotypes, due to linkage 
disequilibrium, it is difficult to say that the patient has anti-
HLA-B8 or anti-HLA-A1 antibodies or both antibodies 
types.  
These problems were overcome by developing 
screening and identification methods based on solid 
phase multiplex platforms (ELISA, flow cytometry, 
luminex) that can detect binding of serum antibodies to 
specific antigens independently of complement activation. 
Also, with these new technologies, using additional anti-
IgM/IgG antibodies, is possible to distinct between IgM 
and IgG anti-HLA antibodies. Additionally, it can 
discriminate between HLA class I and class II antibodies 
and more, single antigen methods allow identification of 
an unique HLA specificity. 
In 1969, Patel and Terasaki demonstrated the 
clinical importance of anti-HLA antibodies. In present is 
very well known that the recipients who present 
preformed cytotoxic antibodies have a high rate of graft 
rejection [5].  It is also true that the individual importance 
of anti-HLA class I and class II antibodies to graft rejection 
is incompletely understood. Some studies show that only 
the presence of both types of antibodies is accompanied 
by a decrease in graft survival, whereas isolated reactivity 
have not clinical consequences [10, 11]. On the other 
hand, several recently reported cases have shown that 
anti-DP antibodies are a potential risk factor for graft 
dysfunction and failure. HLA-DP mismatch between donor 
and recipient does not influence graft function at the first 
kidney transplant but has a negative impact in case of a 
retransplant [12, 13, 14]. 
Binding of specific antibodies to antigens on the 
vascular endothelium followed by complement activation 
represents the main mechanism underlying acute and 
hyperacute rejection. Complement system is activated by 
classical pathway having as final result the membrane 
attack complex – MAC, which lyses endothelial cells 
followed by graft rejection [6]. 
The aim of our study was the systematic pursuit 
of class I and/or class II cytotoxic antibodies 
pretransplant, their de novo appearance post transplant 
(donor or nondonor-specific) and integrating these results 
with serum levels of cytokines (TNF-α, IL-2 Receptor, 
neopterin) and immunosuppressants in order to assess 
the patient's immunological status and subclinical or acute 
rejection episodes.  
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Material and methods 
We evaluated a total of 500 Romanian patients 
registered on the waiting list for renal transplant who 
subsequently received kidney transplantation. We 
performed anti-HLA class I and class II antibodies 
screening in all subjects and in case they were present, 
their identification was made. Laboratory tests were 
performed at Centre for Immunogenetics and Virology, 
Fundeni Clinical Institute, Bucharest, Romania. The 
methods used are represented by ELISA (GTI Diagnosis, 
USA) and Luminex (LifeScreen- Tepnel, USA). 
ELISA is a qualitative solid phase enzyme linked 
immunosorbent assay in that patient serum is added to 
microwells coated with affinity purified HLA class I or 
class II glycoproteins allowing antibodies, if present, to 
bind. Unbound antibodies are then washed away. An 
alkaline phosphatase labeled anti-human globulin reagent 
(anti-IgG) is added to the wells and incubated. The 
unbound anti-IgG is washed away and the substrate 
PNPP (p-nitrophenyl phosphate) is added. After a 30 
minutes incubation period, the reaction is stopped by a 
sodium hydroxide solution. The optical density of the color 
that develops in each microwell is measured in a 
spectrophotometer and compared to a cutoff value. 
LifeScreen is composed of unique Luminex 
Beads to which affinity purified HLA class I and class II 
HLA glycoproteins are conjugated. An aliquot of the 
beads is allowed to incubate with a small volume of 
patient serum. The sensitized beads are then washed to 
remove unbound antibodies. An anti-human IgG antibody 
conjugated to phycoerythrin is then added. After another 
incubation, the test sample is diluted and analyzed on the 
Luminex instrument based on two laser lines. One laser 
identifies each bead and the other captures the 
fluorescent signal emitted by phycoerythrin. The signal 
intensity from each bead is compared to the signal 
intensity of a negative control bead included in the bead 
preparation to determine if the bead is positive or negative 
for bound alloantibodies. 
In addition, postrenal transplant, in patients who 
had de novo cytotoxic antibodies we measured serum 
levels of TNF-α, IL-2 receptor and neopterin by enhanced 
chemiluminescence method using Immulite device. The 
Immulite system assay utilizes specific antibodies or 
antigens coated plastic beads as the solid phase, alkaline 
phosphatase labeled reagent and chemiluminescent 
enzyme substrate. After incubating the sample with the 
alkaline phosphatase reagent, the liquid reaction mixture 
in the Test Unit is rapidly separated from the beads when 
the beads are washed and the Test Unit is spin at a high 
speed on its vertical axis. The entire fluid contents is 
transferred to a coaxial waste chamber in the Test Unit. 
The beads are left with no residual, unbound label. The 
bound label is then quantitated with a dioxetane substrat, 
which produces light. Light emission is detected by a 
photomultiplier tube and printed report for each sample 
are generated by system’s computer.  
Results 
Pretransplant evaluation of the total of 500 
subjects included in our study illustrates that 355 patients 
(71%) have not been sensitized, 85 patients (17%) 
presented anti-HLA class I antibodies, 19 patients (4%) 
presented anti HLA class II antibodies and in 41 subjects 
(8%)  we discovered both types of antibodies. (Figure 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In sensitized patients, next stage was the 
identification of cytotoxic antibodies specificity. Generally, 
the antibody specificity is to a certain epitope (antigenic 
determinant) represented by a short proteic sequence (6-
10 amino acids) of an antigen structure, sequence that is 
recognized by the T or B-cell receptor. Since HLA 
molecule are a very complex structures, with more than 
300 amino acids, it is not surprising they contain multiple 
alloepitopes that are capable of inducing a cellular or 
humoral immune response. Epitopes that originally were 
thought to occur only on a single gene product such as 
HLA-A2 were referred to as private epitopes. Other anti-
HLA antibodies that reacted with more than one gene 
product were through to detect a shared or cross-reactive 
epitope, termed public epitopes. Many of the public 
epitopes are widely distributed among HLA molecules. 
Antibodies to public epitopes have been used to 
categorize HLA gene products into major cross-reactive 
groups (CREG’s).   
In figures 2, 3 and 4 are the percentage of anti-
HLA specificities found in patients in our study group. 
Fig. 1 Anti- HLA class I and class II antibodies distribution 
in study group 
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In our study the most frequently anti-HLA 
specificities were: 
  A2 (13%) followed by A23 and A24 (11 si 
10%) then A25, A26, A32 (about 9%); 
  B42 (10%), B57 (8%), B27, B55, B56, B58 
each with 7 percent; 
  DR7 and DR11 (13%), DR1 and DR4 (11%), 
DR8 and DR10 (10%). 
This distribution is not surprising since the 
corresponding antigens of these antibodies are among 
the most common in the Romanian population and 
therefore the chance that a patient's immune system to be 
sensitized towards these antigens is very high. 
At 1 year post transplant, among the initially 
nonsensitized patients, 303 who had more than 50% 
compatibility af HLA-A, B, DRB1 with donor (i.e. had at 
least three of the six identical alleles) developed de novo 
cytotoxic antibodies in a proportion of 13% (39 patients) 
while the remainder (52 patients) in which donor-recipient 
compatibility was less than 50%, de novo antibodies 
occurred at a rate of 27% (14 recipients). 
In previously immunized patients, the percentage 
who developed de novo post transplant cytotoxic 
antibodies was slightly higher, 32% (46 patients), 
evidenced by PRA (Panel Reactive Antibody) increased. 
Most cases of de novo antibodies appearance 
were observed in the first 6 months post transplantation. 
86% of transplant recipients developed at least one 
episode of acute reject controlled by immunosuppressive 
therapy. We observed that patients under 
immunosuppressive treatment with Prograf (tacrolimus) 
and MMF (mycophenolate mofetil) presented decreased 
rates of cytotoxic antibodies production compared with 
patients under treatment with CsA (cyclosporine A) and 
MMF (mycophenolate mofetil). In addition, subjects under 
immunosuppressive treatment with Rapamune (Sirolimus) 
and MMF (mycophenolate mofetil) presented higher rates 
of cytotoxic antibodies production. 
Colvin et al. [15] revealed that serial monitoring 
of serum levels of Il-2 Receptor (Il-2R) could have 
diagnostic value for detection of post transplant kidney 
rejection. Beutler and Cerami [16] detected high levels of 
serum TNF-α during acute rejection and infections 
periods suggesting that TNF-α could represent a relevant 
mediator of transplant reject. Sometimes, elevated TNF-α 
were found before creatinine levels increase and then 
TNF-α fell rapidly, in 2-3 days after intensive 
immunosuppressive therapy. There are other studies, 
which reveal that serum levels of neopterin are 
persistently high after renal transplantation in uremic 
patients with acute tubular necrosis. In addition, daily 
measurement of this parameter could be useful for 
biochemical detection of immunological complications. 
[17] 
In our group of post transplant sensitized 
patients (n=99), serum levels of IL-2R, TNF- and 
neopterin were in the value ranges represented in the 
graphs in fig. 5, 6 and 7 and high levels were evidenced 
after a variable period of time (2-15 days) following de 
novo HLA antibodies occurrence. 
Fig. 2 Anti-HLA-A cytotoxic antibodies distribution 
 
Fig. 3 Anti-HLA-B cytotoxic antibodies distribution 
Fig. 4 Anti-HLA-DR cytotoxic antibodies distribution Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
  394 
© 2010, Carol Davila University Foundation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussions 
In recent years, there is an increased interest in 
the study of cytotoxic antibodies involved in graft rejection 
in kidney transplantation. In literature, a rate of about 20-
25% of subjects undergoing a kidney transplant shows 
cytotoxic antibody increased titers. In our study, the 
percentage was 19.8%. We found that both, compatible 
and incompatible subjects, postkidney transplantation 
could develop de novo anti-HLA antibodies, predictable 
for acute graft rejection. The most common types of HLA 
antibodies were anti-HLA-A2, 23, 24, HLA-B42, 57, 27, 
HLA-DR7, 11, 1, 4.  Important to note is that recipients 
who developed de novo anti-HLA antibodies associated 
with severe rejection phenomena exhibited increased 
serum levels of TNF - α, IL-2R and neopterin. 
Immunosuppressive therapy based on tacrolimus with 
Mycophenolate mofetil combination is more effective in 
preventing HLA alloimunization post renal transplantation 
than combinations that include cyclosporine or sirolimus 
associated with Mycophenolate mofetil. 
In conclusion, to note that, postkidney transplant, 
recipients have an increased risk of developing de novo 
cytotoxic antibodies, especially those had an HLA 
mismatch with donor, and these antibodies may be 
predictive for acute rejection episodes and graft failure. A 
correct monitoring algorithm postrenal transplantation   
includes: (1) best possible HLA match, (2) detection and 
Fig. 5 IL-2 R serum levels in post transplant sensitized 
patients, (normal range = 223 – 710UI/ml) 
Fig. 6 TNF- serum levels in post transplant sensitized 
patients, (normal range = 0 – 8,1 pg/ml) 
 
Fig. 7 Neopterin serum levels in post transplant sensitized 
patients, (normal range = 0,3 – 3,0 ng/ml) Journal of Medicine and Life Vol. 3, No. 4, October‐December 2010 
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identification of cytotoxic antibodies (3) determining 
cytokine gene polymorphism in conjunction with their 
serum levels (4) monitoring of immunosuppressive 
therapy (5 ) assessment of  serum viral load (CMV, EBV, 
BKV polyoma, parvovirus B19, HBV, HCV). 
 
References 
 
 
 
1.  Feucht HE, Schneeberger H, 
Hillebrand G, Burkhardt K, Weiss 
M, Riethmuller G, Land W, Albert 
E. Capillary deposition of C4d 
complement fragment and early 
renal graft loss. 1993. Kidney Int 
43: 1333 –1338. 
2.  Muczynski KA, Ekle DM, Coder 
DM, Anderson SK. Normal human 
kidney HLA-DR-expressing renal 
microvascular endothelial cells: 
characterization, isolation, and 
regulation of MHC class II 
expression. 2003. J Am Soc 
Nephrol.14: 1336–48. 
3.  Krensky AM, Weiss A, Crabtree 
G, Davis MM, Parham P. T-
lymphocyte-antigen interactions in 
transplant rejection. 1990. N Engl J 
Med 322: 510–517. 
4.  Gebel HM, Bray RA, Nickerson P. 
Pre-transplant assessment of 
donor-reactive, HLA-specific 
antibodies in renal transplantation: 
contraindication vs. risk. 2003. Am J 
Transplant. 3: 1488– 500. 
5.  Patel R, Terasaki PI. Significance 
of the positive crossmatch test in 
kidney transplantation. 1969. N 
Engl J Med 280: 735–9. 
6.  Prodinger WM, Wurzner R, 
Stoiber H, Dierich MP. 
Complement. In: Fundamentals in 
Immunology, edited by Paul WE, 
Philadelphia, Lippincott Williams & 
Wilkins, 2003 , pp1077 –1103. 
7.  Van den Elsen JM, Martin A, 
Wong V, Clemenza L, Rose DR, 
Isenman DE. X-ray crystal structure 
of the C4d fragment of human 
complement component C4. 2002. 
J Mol Biol 322: 1103 –1115. 
8.  Nakashima S, Qian Z, Rahimi S, 
Wasowska BA, Baldwin WM 3rd. 
Membrane attack complex 
contributes to destruction of 
vascular integrity in acute lung 
allograft rejection. 2002. J 
Immunol169: 4620 –4627. 
9.  Murphey CL, Forsthuber TG.   
Trends in HLA Antibody Screening 
and Identification and Their Role in 
Transplantation. 2008. Expert Rev 
Clin Immunol. 4(3): 391-399. 
10.  Süsal C, Pelzl S, Simon T, Opelz 
G.  Advances in pre- and 
posttransplant immunologic testing 
in kidney transplantation. 2004 . 
Transplant Proc. 36(1):29-34. 
11.  Süsal C, Opelz G. Good kidney 
transplant outcome in recipients 
with presensitization against HLA 
class II but not HLA class I. 2004. 
Hum Immunol. 65(8):810-6. 
12.  Thaunat O, Hanf  W, Dubois V et 
al. Chronic humoral rejection 
mediated by anti-HLA-DP 
alloantibodies: insights into the role 
of epitope sharing in donor-specific 
and nondonor-specific 
alloantibodies generation. 
2009.Transpl Immunol. 20: 209-
211. 
13.  Mytilineos J, Deufel A, Opelz G. 
Clinical relevance of HLA-DPB 
locus matching for cadaver kidney 
retransplant. 1997. Transplantation 
63: 1351-4. 
14.  Billen EVA, Christiaans MHL, 
Doxiadis I, Voorter C.  HLA-DP 
antibodies before and after renal 
transplantation. 2009. Tissue 
Antigens . 
15.  Colvin RB, Preffer FI, Fuller TC et 
al. A critical analysis of serum and 
urine interleukin-2 receptor assays 
in renal allograft recipients. 
1989.Transplantation, 48:800. 
16.  Beutler B, Cerami A. The biology 
of cachectin/TNF-alpha, primary 
mediator of the host respons. 1989.  
Annu. Rev. Immunol. 7: 625. 
17.  Lee PH, Huang MT, Chung YC, 
Hu RH, Tzeng SS, Lee CJ, Lee 
CS. Monitoring of serum neopterin 
in renal transplant recipients.1992. 
J Formos Med Assoc. 91(12): 1209-
12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 